Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05971849 · ClinicalTrials.gov registry record · Phase 1
Dampening the Reproductive Axis With Continuous Kisspeptin
A Phase 1 study, sponsored by Stephanie B. Seminara, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05971849: Completed Phase 1 study, sponsored by Stephanie B. Seminara, MD.
NCT05971849 is a Phase 1 study that has completed, run by Stephanie B. Seminara, MD. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05971849, a Phase 1 study, has completed, sponsored by Stephanie B. Seminara, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The goal of this study is to assess response to kisspeptin as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian syndrome (PCOS).
Primary Outcome
Average change in LH pulse frequency before and during kisspeptin infusion
Interventions
- DRUG kisspeptin 112-121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-10-06 |
| Est. Completion | 2024-04-27 |
| Phase | Phase 1 |
What the finished NCT05971849 record still lists
NCT05971849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which kisspeptin 112-121 is the first listed.
NCT05971849 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05971849 about?
NCT05971849 is a clinical study titled "Dampening the Reproductive Axis With Continuous Kisspeptin". The goal of this study is to assess response to kisspeptin as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian syndrome (PCOS).
What is the current status of trial NCT05971849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-10-06. Estimated completion is 2024-04-27.
What interventions are being tested in trial NCT05971849?
The interventions under investigation include: kisspeptin 112-121 (DRUG).
Who is sponsoring clinical trial NCT05971849?
This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05971849's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI